ABBV vs NVS
As of Sep 20, 2026, AbbVie (ABBV) scores 7.8/10 and Novartis (NVS) 5.7/10 on AlphaStocks' five-model composite, so ABBV scores higher. ABBV trades 102% above its model fair value; NVS trades 37% below its model fair value.
ABBV
AbbVie Inc.
7.8
Strong Buy
$263.86
NVS
NOVARTIS AG
5.7
Consider Buy
$140.37
ABBV vs NVS: Which is the Better Investment?
AbbVie Inc. (ABBV) scores 7.8/10 while NOVARTIS AG (NVS) scores 5.7/10 on AlphaStocks' composite model. AbbVie Inc. has the higher composite rating of Strong Buy. On a P/E basis, NOVARTIS AG trades at 19.6x, making it the more attractively priced of the two. NOVARTIS AG trades further below its estimated fair value.
This comparison is algorithmically generated and is not financial advice.
| Metric | ABBV | NVS |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 7.8/10▲ | 5.7/10 |
| Rating | Strong Buy▲ | Consider Buy |
| Price | $263.86 | $140.37 |
| P/E Ratio | 110.7 | 19.6▲ |
| ROE | -143.0% | 31.5%▲ |
| Market Cap | $468B | $274B |
| Fair Value | $130.53 | $223.17 |
| Dividend Yield | 2.7%▲ | 2.6% |
| Sector Rank | #2 of 168▲ | #68 of 168 |
| Model Verdicts | ||
| Piotroski | Strong | Strong |
| Buffett | Strong | Strong |
| Graham | Neutral | Neutral |
| Lynch | Neutral | Strong▲ |
| Greenblatt | Neutral | Attractive▲ |
Related comparisons
ABBV vs NVS: Which Stock Scores Higher?
AbbVie Inc. (ABBV) and NOVARTIS AG (NVS) are both in the Health Care sector. ABBV currently leads with a composite score of 7.8/10 (Strong Buy) compared to NVS's 5.7/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer